Tergus Pharma and MedPharm are now one company!

The two premier topical experts have joined forces to create the world’s leading topical CDMO with global reach, experienced leadership, strong financial backing, and expanded end-to-end capabilities from early stage development through full commercial production of topical drug products.

Click here for the official press release.

Formulation Development

MedPharm offers a variety of formulation development services for dermal, nasal, ophthalmic, and other complex delivery routes. From early-phase discovery to process development, our rigorous approach to formulation development serves to mitigate risk and optimize products prior to reaching costly clinical phases.

API Characterisation

MedPharm supports customers from the very start of the development process to rapidly evaluate any potential risks and suggest mitigation techniques.
API’s are characterized using a variety of physiochemical methods to help advise the customer on the best formulation development strategy for their product.
Information obtained can be used directly in regulatory submissions.

Each model ranks the ability of compounds to penetrate tissue based on key physiochemical information.
Combining in silico investigations with API characterization helps our clients to make informed decisions on compound selection early in the development pathway.
Our in vitro assessments allow compounds to be selected based on activity and permeability in ex vivo human tissue.

In Silico Prediction and In Vitro Assessment

Pre-formulation

Our rigorous approach to understanding potential interactions between APIs and excipients reduces the time and risk associated with formulation development.
Excipients are selected by applying MedPharm’s extensive experience to understanding API characteristics and target product profiles. These excipients are carefully matched to any regional requirements where the final formulation may be marketed.
We assess the solubility of our clients’ compounds in excipients, aiding the selection of compatible solvent systems for the formulation.

Cost-effective analysis of the originator product/RLD so that a new generic product can be clearly demonstrated to match.
MedPharm uses state of the art analytical techniques in tandem with their years of experience to identify the quality and quantity of the excipients in the originator product.
Microstructure of originator product is characterized so it can be duplicated in preliminary process assessment.

Reverse Engineering

Preliminary Process Assessment

Preliminary process assessment is undertaken when developing a generic to match the character of the originator product/RLD.
Many RLDs are sub-optimal formulations but the new generic must still match in order to justify in vitro bioequivalence.
Processing of these formulations can be very sensitive to process parameters so preliminary process assessment reduces cost and increases chances of having a consistent scalable formulation.

MedPharm prepares prototype formulations based on preformulation data and the target product profile, following close consultation with the client.
Multiple formulations in the relevant dosage forms are developed in parallel to ensure that the most appropriate is selected.
The program can be tailored to match customer budget so the maximum benefit for the client is achieved with minimal risk.
Short term stability studies of the compound in excipients or solvent systems are performed to identify potential risks once formulation development is underway.

Formulation Development

Lead Formulation Selection

We don’t just provide data; we help you make sense of it.
Lead candidates are always selected in close consultation with the client. Development goals set at the start of the project are regularly reviewed and risk-assessed to confirm they are still valid.
MedPharm’s development strategy aims to minimize risk and retain flexibility with a lead and back up formulation.